Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Quizartinib in patients with Acute Myeloid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib as a treatment option for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.
This statement is based on a regulatory approval from the Health Service Executive:
As a monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.